Key result
Bisoprolol exposure in patients with Long QT syndrome was associated with a 5.9% rate of minor cardiovascular events over 31 months, compared to 20.6% during nadolol or propranolol treatment.
Why the study?
Does bisoprolol prevent cardiovascular events in patients with Long QT Syndrome compared to no treatment or other beta-blockers?
Observational (n=34)
Does bisoprolol prevent cardiovascular events in patients with Long QT Syndrome compared to no treatment or other beta-blockers?
Absolute Event Rate: 5.9% vs 20.6%
Bisoprolol appears to be as effective as propranolol and nadolol in preventing major cardiovascular events in Long QT Syndrome, while potentially being easier to manage.
No takes yet. Share an insight, caveat, or question.
Bisoprolol may match nadolol/propranolol efficacy with fewer events and better tolerability in LQTS; leaves open need for RCTs before practice change.
Fazio et al. (2013) conducted an observational in Long QT syndrome (LQTS) (n=34). Bisoprolol vs. Nadolol, propranolol, or no treatment was evaluated on Minor cardiovascular events. Bisoprolol exposure in patients with Long QT syndrome was associated with a 5.9% rate of minor cardiovascular events over 31 months, compared to 20.6% during nadolol or propranolol treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: